Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-25T17:46:25.718Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of Medical Comorbidity on Medication Management of Schizophrenia

Published online by Cambridge University Press:  07 November 2014

Dan W. Haupt
Get access Rights & Permissions [Opens in a new window]

Extract

Schizophrenia is associated with increased medical comorbidity likely caused by interactions between life-style, environment, and the disease itself. High rates of medical comorbidity exist among all forms of serious mental illness. Affective disorders such as bipolar disorder and unipolar depression are associated with 1.5–2 times the mortality rate observed in the general population, and high rates of HIV and hepatitis A, B, and C exist among patients with severe mental illness. However, schizophrenia is particularly affected by medical comorbidities, and is associated with a 20% shorter-than-normal lifespan. This discussion focuses on rates of medical comorbidity in people with schizophrenia and the effects of medication on cardiometabolic risk factors. It is also important to recognize that lifestyle and environmental factors associated with serious mental illness, as well as poor access to healthcare, contribute to the elevated rates of medical illnesses observed in these populations as well.

Studies of the association between schizophrenia and medical comorbidities have suggested that the introduction of second-generation antipsychotics (SGAs) may be responsible for the increases observed in cardiovascular disease rates in this patient population, and that cardiovascular disease mortality may be shifting to an earlier stage of life. Ösby and colleagues observed that while overall cardiovascular mortality in schizophrenia patients in Sweden increased from 1976–1995, an even greater increase occurred in men from 1991–1995. This latter increase corresponded temporally to an increased use of SGAs.

Osborne and colleagues recently confirmed the observation made by Osby and colleagues. They compared 46,000 people with serious mental illness and a general population sample of ∼300,000 people from 1987–2002.

Type
Expert Roundtable Supplement
Information
CNS Spectrums , Volume 12 , Issue S21: Inpatient to Outpatient Status: Clinical Considerations in the Transitional Treatment of Schizophrenia , December 2007 , pp. 15 - 17
Copyright
Copyright © Cambridge University Press 2007

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Harris, EC, Barraclough, B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11–53.Google Scholar
2.Meyer, JM. Prevalence of hepatitis A, hepatitis B, and HIV among hepatitis C-seropositive state hospital patients: results from Oregon State Hospital. J Clin Psychiatry. 2003;64(5):540–545.Google Scholar
3.Newman, SC, Bland, RC. Mortality in a cohort of patients with schizophrenia: a record linkage study. Can J Psychiatry. 1991;36(4):239–245.Google Scholar
4.Osby, U, Correia, N, Brandt, L, Ekbom, A, Sparén, P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ. 2000;321(7259):483–484.Google Scholar
5.Osby, U, Brandt, L, Correia, N, Ekbom, A, Sparén R Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry. 2001;58:844–850.CrossRefGoogle Scholar
6.Osborn, DP, Levy, G, Nazareth, I, Petersen, I, Islam, A, King, MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry. 2007;64:242–249.Google Scholar
7.Colton, CW, Manderscheid, RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. Prev Chronic Dis [serial online]. 2006.Google Scholar
8.McEvoy, JP, Meyer, JM, Goff, DC, et al.Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19–32.Google Scholar
9.Nasrallah, HA, Meyer, JM, Goff, DC, et al.Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86(1–3):15–22.Google Scholar
10.Lieberman, JA, Stroup, TS, McEvoy, JP, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209–1223.Google Scholar
11.Weiden, PJ, Newcomer, JW, Loebel, AD, Yang, R, Lebovitz, HE. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone. Neuropsychopharmacology. 2007;[Epub ahead of print].Google Scholar
12.American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus Development Conference on Antipsychotic Drugs and Obesity and Diabetes. Diabetes Care. 2004;27:596–601.Google Scholar
13.Parks, J, Svendsen, D, Singer, P, Foti, ME. Morbidity and Mortality in People with Serious Mental Illness. Alexandria, Va: National Association of State Mental Health Program Directors Medical Directors Council; 2006.Google Scholar